IBI389 + sintilimab

IBI389 + sintilimab is a **combination therapy** under clinical investigation for the treatment of advanced malignancies, especially solid tumors such as gastric, gastroesophageal junction (GEJ), and pancreatic cancers[1][3][4]. - **IBI389** is a bispecific antibody that targets *Claudin18.2* (CLDN18.2), a tight junction protein overexpressed in several gastrointestinal cancers, and *CD3* on T-cells to recruit and activate cytotoxic T-cells for tumor cell destruction[2][3]. - **Sintilimab** is a monoclonal antibody that inhibits *Programmed cell death protein 1* (PD-1), enhancing anti-tumor immune responses[4]. This combination leverages both targeted T-cell engagement and immune checkpoint blockade, seeking synergistic antineoplastic activity. IBI389 is developed by Innovent Biologics. The combination is currently in Phase 1 clinical trials for advanced or metastatic solid tumors, including pancreatic ductal adenocarcinoma and CLDN18.2-positive gastric/GEJ adenocarcinoma[1][3][4]. Preliminary results indicate manageable safety profiles and promising efficacy in patients with CLDN18.2 positivity[3].